Shuttle Pharmaceuticals Inc (SHPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shuttle Pharmaceuticals Inc (SHPH) has a cash flow conversion efficiency ratio of -0.722x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.42 Million) by net assets ($3.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Shuttle Pharmaceuticals Inc (SHPH) market capitalisation for the company's overall valuation and market capitalisation.
Shuttle Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Shuttle Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Shuttle Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shuttle Pharmaceuticals Inc ranked by their cash flow conversion efficiency. See how well can Shuttle Pharmaceuticals Inc service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gabather AB (publ)
ST:GABA
|
-0.117x |
|
Valion Bio Inc
NASDAQ:VBIO
|
-0.444x |
|
Prostemics Co. Ltd
KQ:203690
|
-0.036x |
|
Therma Bright Inc
V:THRM
|
0.026x |
|
Sungmoon Electronics Co Ltd
KO:014915
|
0.037x |
|
Painreform Ltd
NASDAQ:PRFX
|
-0.117x |
|
RIVER TECH EO -005
F:9YQ
|
N/A |
|
Kulthorn Kirby Public Company Limited
BK:KKC
|
0.049x |
Annual Cash Flow Conversion Efficiency for Shuttle Pharmaceuticals Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Shuttle Pharmaceuticals Inc from 2017 to 2025. View Shuttle Pharmaceuticals Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.25 Million | $-9.48 Million | -4.206x | +59.30% |
| 2024-12-31 | $709.15K | $-7.33 Million | -10.332x | -650.85% |
| 2023-12-31 | $4.06 Million | $-5.58 Million | -1.376x | -289.81% |
| 2022-12-31 | $7.68 Million | $-2.71 Million | -0.353x | -291.37% |
| 2021-12-31 | $-1.63 Million | $-300.34K | 0.184x | +1062.10% |
| 2020-12-31 | $-1.69 Million | $-26.83K | 0.016x | +100.08% |
| 2018-12-31 | $27.46K | $-566.69K | -20.640x | -2995.31% |
| 2017-12-31 | $-284.35K | $-202.71K | 0.713x | -- |
About Shuttle Pharmaceuticals Inc
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.